China's medical products administrator granted North China Pharmaceutical (SHA:600812) subsidiary North China Pharmaceutical Hebei Huamin Pharmaceutical marketing approval for its ceftoranil product, according to a Wednesday filing with the Shanghai bourse.

The drug is a cephalosporin antibiotic and is an effective treatment for community-acquired respiratory infections and other diseases such as superficial and deep skin infections, abscesses, pharyngitis and laryngitis, tonsillitis, bronchitis, pneumonia, and other infections, the filing said.